Study on PK-PD Evaluation of Ginsenoside Rb1 in Subjects with Angina Pectoris Following Intravenous Administration of Shengmai Injection
10.11842/wst.2017.05.021
- VernacularTitle:生脉注射液中人参皂苷Rb1在心绞痛患者体内的PK-PD结合模型研究
- Author:
Suxia XIA
;
Rui YANG
;
Si TANG
;
Shiliang ZHANG
;
Xiaoqian DONG
;
Boyu JING
;
Guoxin LI
- Keywords:
Shengmai injection;
ginsenoside Rb1;
angina pectoris;
chromatography-mass spectrometry;
pharmacokinetics;
pharmacokinetics-pharmacodynamics
- From:
World Science and Technology-Modernization of Traditional Chinese Medicine
2017;19(5):837-840
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to establish the pharmacokinetics-pharmacodynamics (PK-PD) model of ginsenoside Rb1 following the intravenous administration of Shengmai injection in subjects with stable angina pectoris.A total of stable angina pectoris were selected and received Shengmai injection for 14 days.Plasma samples were collected at different time points.Plasma concentrations of ginsenoside Rb1 were determined by liquid chromatography-mass spectrometry (LC/MS).The concentration-time curves (AUC) were drawn,and then the PK parameters were calculated.The systolic pressure and diastolic pressure were monitored,and the combined PK-PD model was established based on the theory of effect compartment.The results showed that PK of ginsenoside Rb1 conformed to a mono-compartment model.The effect of Shengmai injection lagged behind the concentrations of ginsenoside Rb1 in plasma.The effect exhibited good correlation with ginsenoside Rb1 in effect compartment.The relationship between effect and plasma concentrations fits the Inhibitory Effect Imax model.It was concluded that the study successfully established the combined PK-PD model of ginsenoside Rb1 in subjects with angina pectoris.The model can efficiently evaluate the effective substance of Shengmai injection.
